– Data to be released at approximately
6:00 p.m. ET, following presentation at 2023 SABCS –
– Conference call to commence at 6:30 p.m. ET –
SAN
JOSE, Calif., Dec. 6, 2023
/PRNewswire/ -- Anixa Biosciences,
Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer, will publicly release new data this evening
from the ongoing Phase 1 clinical trial of its breast cancer
vaccine, which was presented for the first time today at the 2023
San Antonio Breast Cancer Symposium ("SABCS"). All interested
parties are invited to join an upcoming conference call today at
6:30 pm ET to discuss the data.
Anixa is pleased to invite all interested parties to participate
in a conference call today at 6:30 p.m.
ET, during which the new data will be discussed.
Conference Call
Details:
|
Presentation
host:
|
Anixa management,
with special guest speakers (bios below)
|
Date and time:
|
Today, December 6,
2023, at 6:30 p.m. ET
|
Phone access:
|
Registration
Link to receive your dial-in number and unique PIN
|
Webcast:
|
Available at
www.anixa.com under "Events & Presentations"
|
Guest Speakers:
- Jennifer Davis: Ms. Davis is a nurse, wife,
mother of three, and Triple Negative Breast Cancer survivor. She
was diagnosed in 2018 and had chemotherapy, radiation, a double
mastectomy, and was the first person in the world to receive
Anixa's breast cancer vaccine in 2021 through Cleveland
Clinic. Ms. Davis is passionate about preventing breast
cancer for herself and all women.
- H. Michael Shepard,
PH.D.: Dr. Shepard is a Key Opinion Leader in oncology. He has
made seminal contributions to the fields of immunotherapy, gene
therapy of cancer, and precision medicine. Dr. Shepard is best
known as the inventor of the life-saving breast cancer drug
Herceptin® (trastuzumab). Herceptin was the first
monoclonal antibody therapy approved for cancer, and it spawned an
explosion in monoclonal therapies and antibody-drug conjugates for
cancer. Herceptin still generates sales of over $5 billion per year and is one of the
best-selling cancer drugs of all time, having been prescribed for
over 2.3 million breast cancer sufferers. Among his many awards and
honors are the Warren Alpert Foundation Prize from Harvard Medical School and the Lasker-Debakey
Award. The Alpert Award was shared with Dennis Slamon, Axel
Ullrich, and Robert Weinberg
and the Lasker-DeBakey Award was shared with Slamon and Ullrich for
their development of Herceptin. Dr. Shepard is an advisor to
Anixa.
- Brian Leyland-Jones, MBBS, MD, PH.D., FACP, FRCPC:
Dr. Leyland-Jones is also a Key Opinion Leader in oncology. He is a
past Chief of Developmental Therapeutics at the National Cancer
Institute ("NCI") and has served as principal, co-principal, and
co-investigator on more than 100 clinical studies. While at the
NCI, he coordinated the international development of Paclitaxel, a
cancer drug, and while at McGill
University, made numerous contributions to the development
of Herceptin. Dr. Leyland-Jones has served as the director of two
major cancer centers, holding positions as the Founding Chair of
Oncology and Director of the McGill
University Comprehensive Cancer Center (Minda de Gunzberg
Chair), and Director of the Winship Cancer Centre and Associate
Vice President of Health Science at Emory
University (first director to achieve NCI designation in 30
years). Dr. Leyland-Jones is an advisor to Anixa.
About Triple-Negative Breast Cancer
One in eight
women in the U.S. will be diagnosed with an invasive breast cancer
at some point in their lives. Approximately 10-15% of those
diagnoses are TNBC, however TNBC accounts for a disproportionately
higher percentage of breast cancer deaths and has a higher rate of
recurrence. This form of breast cancer is twice as likely to occur
in African-American women, and approximately 70% to 80% of the
breast tumors that occur in women with mutations in the BRCA1 genes
are triple-negative breast cancer.
About Anixa Bioscience's Breast Cancer Vaccine
Anixa's breast cancer vaccine takes advantage of endogenously
produced proteins that have a function at certain times in life,
but then become "retired" and disappear from the body. One such
protein is a breast-specific lactation protein, α-lactalbumin,
which is no longer found post-lactation in normal, aging tissues,
but is present in the majority of triple-negative breast cancers.
Activating the immune system against this "retired" protein
provides preemptive immune protection against emerging breast
tumors that express α-lactalbumin. The vaccine also contains an
adjuvant that activates an innate immune response, which allows the
immune system to mount a response against emerging tumors to
prevent them from growing. This vaccine technology was invented by
the late Dr. Vincent Tuohy, who was
the Mort and Iris November Distinguished Chair in Innovative Breast
Cancer Research in the Department of Inflammation and Immunity at
Cleveland Clinic's Lerner Research Institute. Dr. Tuohy was
inventor of the technology, which Cleveland Clinic exclusively
licensed to Anixa Biosciences. He was entitled to a portion of the
commercialization revenues received by Cleveland Clinic and also
held equity in Anixa.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists of an
ovarian cancer immunotherapy program being developed in
collaboration with Moffitt Cancer Center, which uses a novel type
of CAR- T, known as chimeric endocrine receptor T-cell (CER-T)
technology. The Company's vaccine portfolio includes a novel
vaccine being developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple
negative breast cancer
(TNBC), the most lethal form of the disease –
as well as a vaccine to prevent ovarian cancer. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
unique business model of partnering with world-renowned research
institutions on clinical development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect Anixa's current expectations
concerning future events and results. We generally use the words
"believes," "expects," "intends," "plans," "anticipates," "likely,"
"will" and similar expressions to identify forward-looking
statements. Such forward-looking statements, including those
concerning our expectations, involve risks, uncertainties and other
factors, some of which are beyond our control, which may cause our
actual results, performance or achievements, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10- Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward- looking
statements when evaluating the information presented in this press
release.
Contacts:
Stephen
Kilmer
Investor Relations
skilmer@anixa.com
646-274-3580
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-host-conference-call-this-evening-to-discuss-positive-new-data-from-ongoing-phase-1-study-of-breast-cancer-vaccine-302007540.html
SOURCE Anixa Biosciences, Inc.